| Year |
Citation |
Score |
| 2020 |
Escorcia FE, Houghton JL, Abdel-Atti D, Pereira PR, Cho A, Gutsche NT, Baidoo KE, Lewis JS. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. Theranostics. 10: 151-165. PMID 31903112 DOI: 10.7150/Thno.37098 |
0.342 |
|
| 2019 |
Ray Banerjee S, Minn IL, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess A, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31253744 DOI: 10.2967/Jnumed.119.229393 |
0.331 |
|
| 2018 |
Milenic DE, Kim YS, Baidoo KE, Wong KJ, Barkley R, Delgado J, Brechbiel MW. Exploration of a F(ab') Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy. Cancer Biotherapy & Radiopharmaceuticals. 33: 182-193. PMID 29916748 DOI: 10.1089/Cbr.2018.2434 |
0.348 |
|
| 2017 |
Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW. Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease. Dalton Transactions (Cambridge, England : 2003). PMID 28675216 DOI: 10.1039/C7Dt01819C |
0.363 |
|
| 2017 |
Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW. Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab. Translational Oncology. 10: 535-545. PMID 28577439 DOI: 10.1016/J.Tranon.2017.04.004 |
0.393 |
|
| 2016 |
Kiess A, Minn IL, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel M, Mease RC, Sgouros G, Zalutsky MR, et al. (2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27230930 DOI: 10.2967/Jnumed.116.174300 |
0.313 |
|
| 2016 |
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. International Journal of Molecular Sciences. 17. PMID 27196891 DOI: 10.3390/Ijms17050736 |
0.358 |
|
| 2015 |
Kim YS, Zhou Y, Bryant H, Milenic DE, Baidoo KE, Lewis BK, Frank JA, Brechbiel MW. Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent. Bioorganic & Medicinal Chemistry Letters. 25: 2056-9. PMID 25870133 DOI: 10.1016/J.Bmcl.2015.03.092 |
0.374 |
|
| 2015 |
Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 628-34. PMID 25722448 DOI: 10.2967/Jnumed.114.149062 |
0.316 |
|
| 2015 |
Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. Mabs. 7: 255-64. PMID 25587678 DOI: 10.4161/19420862.2014.985160 |
0.389 |
|
| 2014 |
Zhou Y, Kim YS, Milenic DE, Baidoo KE, Brechbiel MW. In vitro and in vivo analysis of indocyanine green-labeled panitumumab for optical imaging-a cautionary tale. Bioconjugate Chemistry. 25: 1801-10. PMID 25243604 DOI: 10.1021/Bc500312W |
0.361 |
|
| 2014 |
Zhou Y, Kim Y, Milenic DE, Baidoo KE, Brechbiel MW. Abstract 4290:In vitro&in vivoanalysis of indocyanine green-labeled panitumumab for optical imaging: a cautionary tale Cancer Research. 74: 4290-4290. DOI: 10.1158/1538-7445.Am2014-4290 |
0.362 |
|
| 2013 |
Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biotherapy & Radiopharmaceuticals. 28: 441-9. PMID 23758610 DOI: 10.1089/Cbr.2012.1423 |
0.32 |
|
| 2013 |
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212 Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint British Journal of Cancer. 108: 2013-2020. PMID 23632482 DOI: 10.1038/Bjc.2013.189 |
0.345 |
|
| 2013 |
Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nuclear Medicine and Biology. 40: 592-9. PMID 23602604 DOI: 10.1016/J.Nucmedbio.2013.01.010 |
0.336 |
|
| 2013 |
Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. Nuclear Medicine and Biology. 40: 600-5. PMID 23541026 DOI: 10.1016/J.Nucmedbio.2013.01.012 |
0.342 |
|
| 2013 |
Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 530-7. PMID 23230321 DOI: 10.1158/1078-0432.Ccr-12-0298 |
0.35 |
|
| 2013 |
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. International Journal of Radiation Oncology, Biology, Physics. 85: 1119-26. PMID 23200172 DOI: 10.1016/J.Ijrobp.2012.09.015 |
0.346 |
|
| 2013 |
Zhou Y, Baidoo KE, Brechbiel MW. Mapping biological behaviors by application of longer-lived positron emitting radionuclides. Advanced Drug Delivery Reviews. 65: 1098-111. PMID 23123291 DOI: 10.1016/J.Addr.2012.10.012 |
0.333 |
|
| 2013 |
Zhou Y, Kim Y, Milenic DE, Baidoo KE, Brechbiel MW. Abstract 718: Optical molecular imaging of HER1-positive cancer using near-infrared PEGylated indocyanine green-labeled panitumumab. Cancer Research. 73: 718-718. DOI: 10.1158/1538-7445.Am2013-718 |
0.36 |
|
| 2013 |
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Abstract 1601: Paclitaxel potentiates212Pb-radioimmunotherapy-induced cell killing efficacy by perturbing mitotic spindle checkpoint. Cancer Research. 73: 1601-1601. DOI: 10.1158/1538-7445.Am2013-1601 |
0.334 |
|
| 2012 |
Nwe K, Kim YS, Milenic DE, Baidoo KE, Brechbiel MW. (111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an α(v)β(3) Integrin-Binding Radiotracer. Journal of Labelled Compounds & Radiopharmaceuticals. 55: 423-426. PMID 23162207 DOI: 10.1002/Jlcr.2965 |
0.322 |
|
| 2012 |
Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE. Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorganic & Medicinal Chemistry Letters. 22: 5517-22. PMID 22853992 DOI: 10.1016/J.Bmcl.2012.07.024 |
0.314 |
|
| 2012 |
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Molecular Cancer Therapeutics. 11: 639-48. PMID 22238365 DOI: 10.1158/1535-7163.Mct-11-0671 |
0.315 |
|
| 2011 |
Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals (Basel, Switzerland). 5: 1-15. PMID 22229017 DOI: 10.3390/Ph5010001 |
0.405 |
|
| 2011 |
Dadwal M, Kang CS, Song HA, Sun X, Dai A, Baidoo KE, Brechbiel MW, Chong HS. Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates. Bioorganic & Medicinal Chemistry Letters. 21: 7513-5. PMID 22047687 DOI: 10.1016/J.Bmcl.2011.06.107 |
0.366 |
|
| 2011 |
Wong KJ, Baidoo KE, Nayak TK, Garmestani K, Brechbiel MW, Milenic DE. In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers. Ejnmmi Research. 1. PMID 21845232 DOI: 10.1186/2191-219X-1-1 |
0.334 |
|
| 2011 |
Song HA, Kang CS, Baidoo KE, Milenic DE, Chen Y, Dai A, Brechbiel MW, Chong HS. Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications. Bioconjugate Chemistry. 22: 1128-35. PMID 21604692 DOI: 10.1021/Bc100586Y |
0.337 |
|
| 2011 |
Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. Plos One. 6: e18198. PMID 21464917 DOI: 10.1371/Journal.Pone.0018198 |
0.37 |
|
| 2011 |
Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab. International Journal of Cancer. 128: 920-6. PMID 20473899 DOI: 10.1002/Ijc.25409 |
0.353 |
|
| 2011 |
Ray GL, Baidoo K, Keller L, Milenic D, Brechbiel M. Pre-clinical Evaluation of 177Lu-Labeled Trastuzumab Targeting HER2 for Radioimmunotherapeutic and Radioimmunodiagnostic Applications International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.1228 |
0.306 |
|
| 2010 |
Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. Mabs. 2: 550-64. PMID 20716957 DOI: 10.4161/Mabs.2.5.13054 |
0.407 |
|
| 2010 |
Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 942-50. PMID 20484421 DOI: 10.2967/Jnumed.109.071290 |
0.37 |
|
| 2010 |
Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. European Journal of Nuclear Medicine and Molecular Imaging. 37: 1368-76. PMID 20155263 DOI: 10.1007/S00259-009-1370-Z |
0.364 |
|
| 2009 |
Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent British Journal of Pharmacology. 157: 1541-1548. PMID 19681874 DOI: 10.1111/J.1476-5381.2009.00327.X |
0.366 |
|
| 2009 |
Xu H, Eck PK, Baidoo KE, Choyke PL, Brechbiel MW. Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging. Bioorganic & Medicinal Chemistry. 17: 5176-81. PMID 19505829 DOI: 10.1016/J.Bmc.2009.05.048 |
0.383 |
|
| 2009 |
Boswell CA, Regino CA, Baidoo KE, Wong KJ, Milenic DE, Kelley JA, Lai CC, Brechbiel MW. A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging. Bioorganic & Medicinal Chemistry. 17: 548-52. PMID 19101152 DOI: 10.1016/J.Bmc.2008.11.073 |
0.332 |
|
| 2008 |
Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biotherapy & Radiopharmaceuticals. 23: 619-31. PMID 18999934 DOI: 10.1089/Cbr.2008.0493 |
0.359 |
|
| 2008 |
Chong HS, Lim S, Baidoo KE, Milenic DE, Ma X, Jia F, Song HA, Brechbiel MW, Lewis MR. Synthesis and biological evaluation of a novel decadentate ligand DEPA. Bioorganic & Medicinal Chemistry Letters. 18: 5792-5. PMID 18845437 DOI: 10.1016/J.Bmcl.2008.09.063 |
0.371 |
|
| 2008 |
Boswell CA, Regino CA, Baidoo KE, Wong KJ, Bumb A, Xu H, Milenic DE, Kelley JA, Lai CC, Brechbiel MW. Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling. Bioconjugate Chemistry. 19: 1476-84. PMID 18597510 DOI: 10.1021/Bc800039E |
0.337 |
|
| 2008 |
Xu H, Baidoo KE, Wong KJ, Brechbiel MW. A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules. Bioorganic & Medicinal Chemistry Letters. 18: 2679-83. PMID 18359632 DOI: 10.1016/J.Bmcl.2008.03.022 |
0.396 |
|
| 2007 |
Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL, Brechbiel MW. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. Journal of Medicinal Chemistry. 50: 4759-65. PMID 17725340 DOI: 10.1021/Jm070657W |
0.391 |
|
| 2005 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chemistry. 16: 43-50. PMID 15656574 DOI: 10.1021/Bc049820H |
0.577 |
|
| 2004 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate Chemistry. 15: 1416-23. PMID 15546210 DOI: 10.1021/Bc0498267 |
0.563 |
|
| 2004 |
Baidoo KE, Knight LC, Lin KS, Gabriel JL, Romano JE. Design and synthesis of a short-chain bitistatin analogue for imaging thrombi and emboli. Bioconjugate Chemistry. 15: 1068-75. PMID 15366961 DOI: 10.1021/Bc049954V |
0.502 |
|
| 2003 |
Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, Agrawal N, Borzillary S, McCaffery JM, Watson EL, Lin KS, Bunz F, Baidoo K, Pomper MG, Kinzler KW, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proceedings of the National Academy of Sciences of the United States of America. 100: 15083-8. PMID 14657371 DOI: 10.1073/Pnas.2036598100 |
0.524 |
|
| 1998 |
Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner HN. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chemistry. 9: 218-25. PMID 9548537 DOI: 10.1021/Bc9701959 |
0.552 |
|
| 1998 |
Baidoo KE, Scheffel U, Stathis M, Finley P, Lever SZ, Zhan Y, Wagner HN. High-affinity no-carrier-added 99mTc-labeled chemotactic peptides for studies of inflammation in vivo Bioconjugate Chemistry. 9: 208-217. PMID 9548536 DOI: 10.1021/Bc970197T |
0.334 |
|
| 1997 |
Kao CHK, Baidoo KE, Lever SZ. Validation and application of a solid phase chemistry method for preparation of high effective specific activity technetium-99m radiopharmaceuticals Nuclear Medicine and Biology. 24: 499-505. PMID 9316076 DOI: 10.1016/S0969-8051(97)00028-0 |
0.316 |
|
| 1994 |
Del Rosario RB, Jung YW, Baidoo KE, Lever SZ, Wieland DM. Synthesis and in vivo evaluation of a 99m 99Tc-DADT-Benzovesamicol: a potential marker for cholinergic neurons Nuclear Medicine and Biology. 21: 197-203. PMID 9234283 DOI: 10.1016/0969-8051(94)90009-4 |
0.344 |
|
| 1994 |
Lever SZ, Baidoo KE, Mahmood A, Matsumura K, Scheffel U, Wagner HN. Novel technetium ligands with affinity for the muscarinic cholinergic receptor Nuclear Medicine and Biology. 21: 157-164. PMID 9234278 DOI: 10.1016/0969-8051(94)90004-3 |
0.317 |
|
| 1994 |
Baidoo KE, Lever SZ, Scheffel U. Bifunctional chelator for facile preparation of neutral technetium complexes Bioconjugate Chemistry. 5: 114-118. PMID 8031873 DOI: 10.1021/Bc00026A600 |
0.339 |
|
| 1990 |
Baidoo KE, Lever SZ. Synthesis of a diaminedithiol bifunctional chelating agent for incorporation of technetium-99m into biomolecules Bioconjugate Chemistry. 1: 132-137. PMID 2095211 DOI: 10.1021/Bc00002A007 |
0.325 |
|
| Show low-probability matches. |